SULFATION PATHWAYS: Potential benefits of a sulfated resveratrol derivative for topical application

• Published in: Journal of molecular endocrinology Vol. 61; no. 2; pp. M27 - M39
• Main Authors: Correia-da-Silva, Marta, Rocha, Verónica, Marques, Cláudia, Deus, Cláudia M, Marques-Carvalho, Adriana, Oliveira, Paulo J, Palmeira, Andreia, Pinto, Madalena, Sousa, Emília, Sousa Lobo, José Manuel, Almeida, Isabel Filipa
• Format: Journal Article
• Language: English
• Published: England Bioscientifica Ltd 01-08-2018; Society for Endocrinology & BioScientifica Ltd
• Subjects: Aging; Antioxidants; Cytotoxicity; Free energy; Inflammation; Oxidative stress; Resveratrol; SIRT1 protein; Skin; Sulfate; Thematic; Topical application; Western blotting; topical antioxidants; resveratrol; cytotoxicity; sirtuin modulation
• ISSN: 0952-5041; 1479-6813
• DOI: 10.1530/JME-18-0031

Resveratrol (RSV) is a polyphenolic compound with antioxidant, anti-inflammatory and anti-aging properties partly associated with sirtuin 1 (SIRT1)-activation in the skin. However, poor water solubility may limit RSV efficacy. This work aimed to clarify the interest of a new synthetic water-soluble RSV derivative (resveratrol glucoside sulfate, RSV-GS) for topical application. Resveratrol glucoside sulfate was synthesized using microwave-assisted sulfation. Cytotoxicity assays were performed with the keratinocyte HaCaT cell line, using MTT reduction, neutral red uptake, Alamar Blue/resazurin reduction, trypan blue exclusion and measurement of ATP concentration. Western blotting was used to evaluate SIRT1 protein content. Regarding SIRT1 binding, an in silico docking study was performed, using AutoDock Vina. Our results showed that the synthetic derivative RSV-GS was 1000 times more soluble in water than RSV and its non-sulfated glucoside. No relevant decrease in HaCaT cell viability was observed for concentrations up to 5 mM for RSV-GS, and up to 500 μM for resveratrol glucoside, while a significant decrease in HaCaT viability occurred from 100 μM for RSV. RSV-GS and RSV showed a similar behavior regarding protective effect against oxidative stress-induced cytotoxicity. SIRT1 protein content increased after treatment with 500 μM of RSV-GS and 100 μM of RSV. Moreover, in silico studies predicted that RSV-GS binds more stably to SIRT1 with a lower binding free energy than RSV. Although these results support the possible use of RSV-GS in topical formulations, in vivo safety and efficacy studies are needed before considering the use of RSV-GS in commercial products.